CVKD
NASDAQ
$2.09
Cadrenal Therapeutics Inc (CVKD)
Cadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical firm dedicated to developing groundbreaking therapies for renal diseases and associated disorders. Leveraging its proprietary drug platforms, the company is advancing a strong pipeline aimed at fulfilling significant unmet medical needs within renal health. With a focus on scientific innovation and a commitment to patient-centered solutions, Cadrenal is strategically positioned for transformative contributions to patient care, highlighting its substantial growth potential in the dynamic biopharmaceutical sector.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $27.67 (+1223.92%)
Market Cap
$5.89M
Beta (5Y)
1.12
Price Chart
Valuation
Market Cap$5.89M
P/B4.17
Profitability
EBITDA-$12M
EPS-$5.43
Growth & Risk
Beta (5Y)1.12
Sharpe Ratio-1.24